<DOC>
	<DOCNO>NCT02446093</DOCNO>
	<brief_summary>The study investigate addition GMCI neoadjuvant mFOLFIRINOX + chemoradiation safe improve clinical outcome borderline resectable unresectable locally advanced pancreatic adenocarcinoma , measure resection rate , progression-free survival overall survival .</brief_summary>
	<brief_title>Neoadjuvant GMCI Plus mFOLFIRINOX Chemoradiation Non-Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>The current protocol design delivery multiple course GMCI time series neoadjuvant debulking therapies- modify FOLFIRINOX ( mFX ) chemotherapy follow gemcitabine-radiation ( GR ) follow surgery- capitalize synergy different treatment modality . This protocol include two phase : Phase 1b follow Phase 2 . The Phase 1b evaluates safety feasibility mFX+GR+surgery combination GMCI . Patients enrol Phase 1b base definition dose limit toxicity ( DLT ) , wait period stop rule describe protocol . The Phase 2 randomize study compare test group receive GMCI add mFX+GR+surgery control arm receiving mFX+GR follow surgery .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>Pathological diagnosis pancreatic adenocarcinoma first treatment may enrol presumed diagnosis base clinical radiologic evaluation confirmation make biopsy time EUS prior AdVtk injection Patients must deem adequate health undergo major surgery ( pancreaticoduodenectomy ) Tumor accessible injection classify borderlineresectable locally advanced consider potentially resectable central review surgical investigator . Resection may include major vascular resection reconstruction need . Age 1876 year Performance status ECOG 01 SGOT ( AST ) &lt; 3x upper limit normal Total bilirubin ≤2mg/dl Creatinine &lt; 2mg/dl Calculated creatinine clearance &gt; 30ml/m WBC &gt; 3000/mm3 Absolute neutrophil count ( ANC ) &gt; 1500/mm3 Platelets &gt; 100,000/mm3 Hemoglobin &gt; 9 g/dL . Patients must give study specific inform consent prior enrollment Baseline peripheral sensory neuropathy ≥ grade 2 Primary hepatic dysfunction include know cirrhosis active hepatitis . Patients biliary obstruction must stented prior initiate treatment . Evidence clinically significant pancreatitis determine investigator Evidence significant ascites determine investigator Patients systemic corticosteroid ( &gt; 10 mg prednisone per day equivalent ) systemic immunosuppressive drug Known HIV+ Pregnant breastfeeding . Female patient childbearing age must negative serum urine pregnancy test within 1 week begin therapy . Other current malignancy ( except squamous basal cell skin cancer ) Prior abdominal radiation therapy prior chemotherapy pancreatic cancer Other serious comorbid illness compromise organ function Known sensitivity allergic reaction acyclovir valacyclovir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>pancreas</keyword>
	<keyword>pancreatic adenocarcinoma</keyword>
	<keyword>GMCI</keyword>
	<keyword>AdV-tk</keyword>
	<keyword>aglatimagene besadenovec</keyword>
</DOC>